# Material Safety Data Sheet

### **Effective Date:** 09/04/2025

#### Due Date: 08/04/2028

Section 1 : Chemical Product Company Identification	
Product Name	MRBRC-11
CAT No.	KMM003015
CAS No.	Not Available
Identified uses	Pharmaceutical Reference Standard
Details of the Supplier Company	K. M. PHARMA SOLUTION PRIVATE LIMITED Unit No.101, Shivam Industrial park, Sarkhej-bavala NH=8A, At-Moraiya, Changodar, Ahmedabad (Gujarat), India-382213
Telephone	+91 9898822121
	Y

Section 2 : Chemical	Information
Chemical Name	(R)-2-(2-Aminothiazol-4-yl)-N-(4-(2-((4-(2-((2-hydroxy-2- phenylethyl)amino)ethyl)phenyl)amino)-2-oxoethyl)thiazol-2- yl)acetamide hydrochloride
CAS No.	Not Available
Molecular Weight	536.7 : 36.5
Molecular Formula	C26H28N6O3S2 : HCI

Section 3 : Hazards Identification		
Emergency Overview:	Emergency Overview:	
Appearance	Off White Solid	
Target Organs	NA	
Potential Health Effects:		
Eye	NIL	
Skin	NIL	
Ingestion	NIL	
Inhalation	NIL	
Chronic	NIL	



# Section 4 : First Aid Measures

Eye	Wash with plenty of water
Skin	Wash with plenty of water
Ingestion	Medical assistance for gastric lavage.
Inhalation	Remove to fresh air, artificial respiration or oxygen if necessary.
Notes to Physician	Mirabegron EP Impurity D can be washed with plenty of water in case of any exposure

Section 5 : Firefighting Measures	
Extinguishing Media	Carbon dioxide, dry chemical powder, foam, water,
Unusual Fire and Explosion Hazards	None indicated

Section 6 : Accidental Release Measures	
Personal Precautions	Wear self-contained breathing apparatus, avoid dust formation.
Spills/Leaks	Wash with plenty of water, provide adequate ventilation.

Section 7 : Handlings and Storage		
Handling	Wear surgical gloves	
Storage	~Storage	

Section 8 : Exposure Controls, Personal Protection	
Respiratory Protection	Self-contained breathing apparatus
Exposure Limits	NA
Eye Protection	Wear safety goggles
Other Protective Equipment	Protective clothing
Skin	Full sleeves apron
Clothing	Cotton

Section 9 : Physical and Chemical Properties	
Appearance	Off White Solid
Odor	NA
Melting Point	NA



рН	NA	
Vapor Pressure	NA	
Vapor Density	NA	
Evaporation Rate	NA	
Viscosity	NA	
Boiling Point	NA	
Decomposition Temp	NA	
Auto ignition Temp.	NA	
Flash Point	NA	
NFPA Rating	NA	
Flash PointNANFPA RatingNAExplosion LimitsNALowerNA		
Lower	NA	
Upper	NA	
Solubility	*Refer in Additional information	
Specific Gravity/Density	NA	

# Section 10 : Stability and Reactivity

Chemical Stability	~ChemicalStability
Conditions to avoid	Direct contract to skin
Incompatibilities with other Materials	Кеер аway
Hazardous Decomposition Products	NIL
Hazardous Polymerization	NIL

# Section 11 : Toxicological Information

CAS	NA
LD50/LC50	>10,000 mg/kg Remarks: Behavioral:Somnolence (general depressed activity)
Carcinogenicity	NIL
Epidemiology	NIL
Teratogenicity	NIL
Reproductive Effects	NIL
Neurotoxicity	NIL



Mutagencity	NIL
Other Studies	NA

## Section 12 : Ecological Information

Data not available

## Section 13 : Disposal Consideration

**RCRA P-Series** 

Can be incinerated

NA

**RCRA U-Series** 

## Section 14 : Transport Consideration

1

UN-Number	
ADR/RID: IMDG: IATA:	
UN proper shipping name	
ADR/RID: Not dangerous goods IMDG: Not dangerous goods IATA: Not dangerous goods	
Transport hazard class(es)	
ADR/RID: IMDG: IATA:	
Packaging Group	
ADR/RID: IMDG: IATA:	
Environmental hazards	
ADR/RID: No IMDG Marine pollutant: No IATA: No	
Special precautions for users	
Further information	

Section 15 : Regulatory Information	
TSCA	Attached the letter
Health & Safety Reporting List	No data available
Chemical Test Rules	Chemical analysis report is attached



### Section 16 : Additional Information

This product is not bioactive, non-radioactive. It is for R&D use only. Not for drug, household or other uses.

The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. The information in this document is based on the present state of our knowledge. It does not represent any guarantee of the product.

K.M. Pharma Solution Privato Limited

Pharma Control